Biotech Startups

Algenie develops helical photobioreactor technology to lower the cost of algae production at scale, converting CO2 into raw materials for feed, fuel, plastics, and building materials. The company targets industrial and climate-tech applications, positioning algae as a sustainable, economically viable feedstock, and is based in Australia.

1 investor

Algenist develops algae-based skincare products, including anti-aging creams, serums, and treatments built around its proprietary Alguronic Acid compound derived from microalgae. It sells clinically tested cosmetic products directly to consumers.

1 investor

Algiax Pharmaceuticals is a clinical-stage biotech company developing small-molecule GABAA receptor modulators to treat neuropathic pain and other conditions with high unmet medical need. The company's lead candidate AP-325 is in Phase 2 clinical trials for chronic neuropathic pain.

1 investor

Algicel produces Azora, a natural astaxantin dietary supplement extracted from the freshwater microalga Haematococcus Pluvialis grown in the Azores, sold as softgel capsules and an emulsion. The products are marketed as antioxidant and anti-inflammatory supplements for immune, cardiovascular, joint, and cellular health for children and adults in Portugal.

1 investor

Algiplex develops synthetic microbial ecosystems designed to boost microalgae biomass yields for algae producers, improving culture growth rate and resistance to culture crash events with minimal additional nutrient or energy costs. The company operates in the biotechnology and bioproduction sector.

1 investor

Algonist is a pre-clinical stage biotechnology company developing novel small molecule drugs to treat chronic pain without addiction risk. The company targets the large unmet medical need of chronic pain management, particularly in patients who fail standard analgesic treatments.

1 investor

Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH. Its pipeline targets conditions that are major causes of liver cancer and liver-related illness worldwide.

1 investor

AlkaLi Labs develops microbial hyperaccumulators that extract critical minerals, including lithium, from industrial waste streams to supply materials needed for green energy hardware and electrification. The company positions its approach as a low-impact alternative mining method sourcing minerals from dilute and contaminated waste.

1 investor

Alkermes develops pharmaceutical medicines for psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders. The company leverages neuroscience expertise to create treatments for patients with complex conditions that are traditionally underserved.

1 investor

Allelica develops multi-ancestry polygenic risk scores and a cloud and on-premise software platform for clinical genomic risk prediction of common diseases. The platform is used by physicians and health systems in the US and internationally for earlier genomic risk stratification.

1 investor

1 investor

Allentown designs and manufactures laboratory equipment for washing and drying animal cages, racks, bottles, and related research facility supplies. The company offers multiple washer series including EQUINOX, BetterBuilt, and related models tailored for animal research facilities.

1 investor

Allero Therapeutics is a biotech company focused on immunotherapy solutions for allergy and immune-mediated disorders, particularly Celiac Disease. The company is led by experienced pharmaceutical and biotech executives with deep expertise in immunotherapy R&D and allergen management.

1 investor

Alleva Animal Health develops and supplies parasite control products for livestock and pets, sold through rural veterinary practices, with brands including BOSS, CATOLYST, TURBO, and EPRISURE. The company operates a formulation laboratory and serves veterinarians, farmers, and pet owners across New Zealand and Australia.

1 investor

Allied Carbon Solutions develops and manufactures sophorolipids, a natural biosurfactant, with applications in livestock feed and emulsifiers, personal care yeast-fermentation extracts, and agricultural biostimulants. The company conducts research and production of biosurfactant-based ingredients for the agriculture, animal husbandry, and personal care industries.

1 investor

Alligator Bioscience AB is a biotechnology company whose shares are listed on NASDAQ Stockholm (Small Cap) under the ticker ATORX. This page presents investor information about the company's stock and shareholder register.

1 investor

Allonnia applies industrial biology—screening microbes and engineered proteins that interact with metals—to recover copper, nickel, and rare earths from ore and mine waste streams like coal ash, tailings, and acid mine drainage. Its bolt-on systems (D-Solve and RE-Cover) attach to existing mine flowsheets for mining operators to increase metal grade and recovery.

1 investor

Alloplex Biotherapeutics develops a non-engineered autologous cellular therapy for cancer, built on its ENLYST immune cell training platform and lead candidate SUPLEXA, which trains a patient's peripheral blood cells ex vivo to create anti-tumor therapeutic cells. The company operates in the immuno-oncology and cell therapy space and has completed a Phase 1 clinical trial across multiple tumor types.

1 investor

Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing retinal disease treatments, specifically engineered biologics for wet AMD, diabetic eye disease, and retinal vein occlusion. The company focuses on reducing patient treatment burden through extended-duration therapies that require fewer clinic visits.

1 investor

ALLOX develops an AI-enabled platform that uses high-throughput genomics and machine learning to discover biophysical parameters governing protein function for drug discovery. The company focuses on identifying allosteric drug targets to enable development of therapies for previously undruggable proteins.

1 investor

AllRock Bio is a drug development company advancing novel therapies for pulmonary hypertension, interstitial lung diseases, and other fibrotic conditions. Its lead program is an orally administered pan-ROCK inhibitor being investigated in pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease.

1 investor

Alltrna develops engineered, chemically modified tRNA oligonucleotides as programmable medicines, using proprietary machine learning tools to design tRNA molecules with desired pharmacologic properties. Its initial therapeutic focus is treating nonsense mutations by reading through premature termination codons to restore full-length protein production, addressing a category it calls Stop Codon Disease.

1 investor

Allumbra combines quantum sensing technology with AI to analyze blood samples for early cancer detection. The company develops liquid biopsy tests that identify molecular signals of cancer before tumors become visible.

1 investor

Ally Bridge Group is a healthcare investment management firm investing across the global life sciences industry through complementary private equity and public equity strategies. It operates across the capital structure with offices in New York and Hong Kong, serving investors seeking exposure to healthcare innovation.

1 investor